search
Back to results

Nasal Xylitol in the Prevention of Otitis Media

Primary Purpose

Otitis Media

Status
Active
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Xylitol spray
Sponsored by
Rambam Health Care Campus
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Otitis Media

Eligibility Criteria

1 Year - 5 Years (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

1. Children at the age of 1-5 years that suffered from recurrent otitis media (3 episodes in the last 6 months prior to entrance to the study)

Exclusion Criteria:

  1. Children with immune deficiency
  2. Children with craniofacial malformations
  3. Children with chronic otitis media
  4. Children that received prophylactic antibiotic treatment prior to entering the study (3 months )

Sites / Locations

  • Rambam Health Care Campus
  • Carmel Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Xylitol spray

Arm Description

Xylitol nasal spray ( Xlear ltd which contains 10% of Xylitiol) given 3 times a day (one puff for each nostril) for three months period.

Outcomes

Primary Outcome Measures

prevalence of otitis media episodes
The number of events of acute otitis media during the study period of 6 months. The comparison is in 3 months intervals. pre-treatment, during treatment and post-treatment

Secondary Outcome Measures

Side effects of treatment
any side effects of the treatment will be recorded

Full Information

First Posted
October 29, 2015
Last Updated
May 31, 2023
Sponsor
Rambam Health Care Campus
Collaborators
Carmel Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT02592382
Brief Title
Nasal Xylitol in the Prevention of Otitis Media
Official Title
Nasal Xylitol for Recurrent Otitis Media
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
May 1, 2019 (Actual)
Primary Completion Date
August 1, 2023 (Anticipated)
Study Completion Date
September 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Rambam Health Care Campus
Collaborators
Carmel Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Acute otitis media (AOM) is one of the most prevalent and costly illnesses in children throughout the world. AOM can lead to chronic otitis media with effusion (OME) resulting in conductive hearing loss that can cause speech, language, academic, and social developmental delays. Complementary and alternative medicines are being widely used for prevention of AOM. Xylitol is a five carbon polyol (sugar alcohol) produced from natural plants and is used for preventing dental caries and AOM in children. It is commercially available in chewing gums, syrups and toothpastes washes, and other products. Xylitol was shown in several studies to prevent the culture of bacteria in the nasopharynx and oral cavity. It was proven to eliminate the ability of bacteria to attach to the mucosa of the upper respiratory system. It was proven to reduce the ability of bacteria to attach to the mucosa of the upper respiratory system. Previous study had shown that oral usage of Xylitol (as chewing gum or syrup) can reduce the incidence of rAOM by 30% as compared to placebo. But this treatment did not gain popularity since the initial clinical trial 30 years. There are several potential reasons for that. First, Xylitol should be administrated 5 times daily in order to be effective. Study that checked usage of oral Xylitol 3 times daily in children with rAOM did not find additional advantage as compared to placebo. Secondly, by using Xylitol orally we rely on the gut absorption and systemic distribution. Xylitol absorbs poorly in the gut and can cause some GI symptoms (like nausea and diarrhea) especially when used in a syrup (the preferred way in small children). In this study the investigators aim to test the yield of Xylitol nasal spray as a preventive treatment in children with rAOM. By using Xylitol as nasal spray we deliver the active compound directly to the action site (nasopharynx- the AOM reservoir) and avoid the GI side effects

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Otitis Media

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
70 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Xylitol spray
Arm Type
Experimental
Arm Description
Xylitol nasal spray ( Xlear ltd which contains 10% of Xylitiol) given 3 times a day (one puff for each nostril) for three months period.
Intervention Type
Dietary Supplement
Intervention Name(s)
Xylitol spray
Intervention Description
xylitol nasal spray will be administered to this arm three times daily for three months
Primary Outcome Measure Information:
Title
prevalence of otitis media episodes
Description
The number of events of acute otitis media during the study period of 6 months. The comparison is in 3 months intervals. pre-treatment, during treatment and post-treatment
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Side effects of treatment
Description
any side effects of the treatment will be recorded
Time Frame
3 months
Other Pre-specified Outcome Measures:
Title
Antimicrobial treatment
Description
Collect the type (systemic or topical) of antimicrobial treatment prior and during the study
Time Frame
9 months
Title
Parental diary
Description
The parents will conduct a diary that will include AOM episodes, who made the diagnosis, what were the symptoms and what kind of treatment was given.
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
5 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 1. Children at the age of 1-5 years that suffered from recurrent otitis media (3 episodes in the last 6 months prior to entrance to the study) Exclusion Criteria: Children with immune deficiency Children with craniofacial malformations Children with chronic otitis media Children that received prophylactic antibiotic treatment prior to entering the study (3 months )
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Arie Gordin, MD
Organizational Affiliation
Rambam Health Care Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Rambam Health Care Campus
City
Haifa
ZIP/Postal Code
31096
Country
Israel
Facility Name
Carmel Medical Center
City
Haifa
Country
Israel

12. IPD Sharing Statement

Learn more about this trial

Nasal Xylitol in the Prevention of Otitis Media

We'll reach out to this number within 24 hrs